文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌SBRT、HDR-BT与LDR-BT后PSA动力学及生化控制的多机构分析

Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
PubMed 文献 · Radiother Oncol · 2020-07-11

该回顾性多机构分析纳入3502例未接受 upfront ADT 的低危、有利中危和不利中危前列腺癌患者,比较SBRT、HDR-BT和LDR-BT后的PSA动力学与生化复发无生存(BCRFS)。中位随访72个月,LDR-BT较SBRT和HDR-BT导致更低的PSA最低点(nPSA)且持续下降时间更长,但三种 modality 的BCRFS相似;4年后PSA持续下降预测持久的生化控制。

要点

  • LDR-BT较SBRT和HDR-BT导致更低的nPSA和更长的持续下降时间。
  • 三种放疗方式的BCRFS相似,无显著差异。
  • 4年后PSA持续下降可预测持久的生化控制。

核心结论

  • LDR-BT较SBRT和HDR-BT导致更低的nPSA且持续下降时间更长,但三种方式的BCRFS无差异。

研究设计与样本

  • 回顾性分析10家机构1990至2017年3502例未接受upfront ADT的低危、有利中危和不利中危前列腺癌患者,分别接受SBRT(1716例)、HDR-BT(512例)或LDR-BT(1274例)。

主要发现

  • 中位随访72个月,nPSA和nPSA<0.2 ng/mL的达成按风险组分层(交互p≤0.001)。
  • SBRT后中位nPSA为0.2 ng/mL(44个月),HDR-BT后为0.1-0.2 ng/mL(37个月),LDR-BT后为0.01-0.2 ng/mL(51个月);低危/有利中危组中LDR-BT vs SBRT或HDR-BT的平均对数nPSA p≤0.009。
  • 4年时nPSA<0.4 ng/mL的比例无差异(p≥0.51)。
  • 三种方式的BCRFS相似(p≥0.27)。
  • 4年后PSA持续下降预测持久的生化控制。

临床怎么用

  • 临床解读前列腺癌消融性放疗后PSA动力学时需考虑 modality 差异,LDR-BT后PSA下降更慢更低。
  • 4年后PSA持续下降可作为持久生化控制的预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Stereotactic body radiation therapy (SBRT), low dose rate brachytherapy (LDR-BT) and high dose rate brachytherapy (HDR-BT) are ablative-intent radiotherapy options for prostate cancer (PCa). These vary considerably in dose delivery, which may impact post-treatment prostate-specific antigen (PSA) patterns and biochemical control. We compared PSA kinetics between SBRT, HDR-BT, and LDR-BT, and assessed their relationships to biochemical recurrence-free survival (BCRFS). METHODS AND MATERIALS: Retrospective PSA data were analyzed for 3502 men with low-risk (n = 2223; 63.5%), favorable intermediate-risk (n = 869; 24.8%), and unfavorable intermediate-risk (n = 410; 11.7%) PCa treated with SBRT (n = 1716; 49.0%), HDR-BT (n = 512; 14.6%), or LDR-BT (n = 1274; 36.4%) without upfront androgen deprivation therapy at 10 institutions from 1990 to 2017. We compared nadir PSA (nPSA), time to nPSA, achievement of nPSA <0.2 ng/mL and <0.5 ng/mL, rates of nPSA <0.4 ng/mL at 4 years, and BCRFS. RESULTS: Median follow-up was 72 months. Median nPSA and nPSA <0.2 ng/mL were stratified by risk group (interaction p ≤ 0.001). Median nPSA and time to nPSA were 0.2 ng/mL at 44 months after SBRT, 0.1-0.2 ng/mL at 37 months after HDR-BT, and 0.01-0.2 ng/mL at 51 months after LDR-BT (mean log nPSA p ≤ 0.009 for LDR-BT vs. SBRT or HDR-BT for low/favorable intermediate-risk). There were no differences in nPSA <0.4 ng/mL at 4 years (p ≥ 0.51). BCRFS was similar for all three modalities (p ≥ 0.27). Continued PSA decay beyond 4 years was predictive of durable biochemical control. CONCLUSION: LDR-BT led to lower nPSAs with longer continued decay compared to SBRT and HDR-BT, but no differences in BCRFS.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Levin-Epstein R, Cook RR, Wong JK, et al. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiother Oncol. 2020. PMID: 32663537. doi:10.1016/j.radonc.2020.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。